Global Ovarian Cancer Diagnostics Market
Ovarian Cancer Diagnostics is the disease characterized by the abnormal growth of cells in the ovarian tissue. Ovarian Cancer Diagnostics Market is the most common type of cancer in the women. Types of ovarian cancer include a stromal tumour, germ cell tumour, and epithelial tumours. Symptoms associated with ovarian cancer include abdominal pressure, swelling, loss of appetite, urinary urgency, low back pain, and pelvic discomfort among others. Ovarian cancer can be diagnosed by MRI, CT, PET scans, blood tests, ultrasound, and pelvic examination.
Increase in the ageing women population, rise in technological advancements for disease diagnosis, increase in the prevalence of ovarian cancer around the globe, and rise in healthcare awareness among key stakeholders are anticipated to bolster the ovarian cancer diagnostics market. Furthermore, highly developed healthcare infrastructure in developed countries, a rise in income per capita, and government initiative programs for increasing awareness about the ovarian cancer are expected to boost the ovarian cancer market growth over the forecast period. However, a high cost of the diagnostic procedure, lack of accuracy in disease diagnosis, stringent regulatory policies for diagnostic device approvals, and lack of early diagnostic tests and early warning systems might hamper the ovarian cancer diagnostics market over the forecast timeframe.
Ovarian cancer diagnostics market is segmented on the basis of diagnosis type, disease type, and end user
Based on the diagnosis type, ovarian cancer diagnostics market is segmented into the following:
- Biopsy
- MRI scan
- CT scan
- PET scan
- Ultrasound
- Blood test
- Others
Based on the disease type, ovarian cancer diagnostics market is segmented into the following:
- Stromal tumour
- Germ cell tumour
- Epithelial tumour
- Primary peritoneal carcinoma
Based on the end user, ovarian cancer diagnostics market is segmented into the following:
- Hospitals
- Clinics
- Diagnostic Centres
- Others
Ovarian cancer diagnostics market is growing at a significant CAGR owing to increase in the prevalence of ovarian cancer around the globe. According to World Cancer Research Fund International, about 239,000 new cases were diagnosed in 2012. Acquisitions and mergers, collaborations, innovation of novel diagnostic procedures are key strategies followed by the companies for increasing their revenue. For instance, In January 2015, VolitionRx Ltd. collaborated with Singapore General Hospital for development of the blood-based test for ovarian cancer diagnosis. Moreover, fundraising by the market players for the innovation of novel diagnostic procedures also propels the market growth.
Geographically, ovarian cancer diagnostics market is segmented into North America, Asia Pacific, Europe, the Middle East and Africa, and Latin America. Due to increase in the prevalence of ovarian cancer in U.S. (according to Centres for Disease Control and Prevention 2014, about 21,161 women diagnosed and 14,195 women died of ovarian carcinoma), a rise in the healthcare expenditure are propelling the ovarian cancer diagnostics market growth in North America region. Europe exhibiting significant growth in ovarian cancer diagnostics market which is attributed to the upsurge in ageing women population, highly developed healthcare infrastructure, an increase in the disease prevalence majorly in Estonia, Latvia, Lithuania, and Croatia are expected to fuel the ovarian cancer diagnostics market. ‘Asia Pacific holds significant share owing to rise in ageing women population majorly in Japan, China, and India, increase in the healthcare expenditure, and adoption of novel techniques for diagnosis.
Some of the players in the ovarian cancer diagnostics market are AstraZeneca Plc. (U.K.), Illumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Siemens AG (Germany), Roche Holding AG (Switzerland), Myriad Genetics, Inc. (U.S.), Epigenomics AG (Germany), Thermo Fischer Scientific Inc. (U.S.), VolitionRx Ltd. (Singapore), and Abcodia Ltd. (U.K.) to name a few.
- In May 2015, Abcodia secured funding about £5.25 Mn to launch Roca test for early detection of the ovarian cancer
Report Outline:
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
